Quince Therapeutics, Inc. (QNCX)
3.60
+0.08
(+2.27%)
USD |
NASDAQ |
Dec 04, 16:00
3.64
+0.04
(+1.11%)
Pre-Market: 08:08
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 200.45M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 80.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 189.32 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 16.99 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.55% |
Profile
| Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA. |
| URL | http://quincetx.com |
| Investor Relations URL | https://ir.quincetx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 23, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA. |
| URL | http://quincetx.com |
| Investor Relations URL | https://ir.quincetx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 23, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |